Direct oral anticoagulants and antiplatelet agents: Clinical relevance and options for laboratory testing

Hamostaseologie

Volumn 34, Issue 1, 2014, Pages 78-84

  Sibbing, D ^a   Spannagl, M ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Drug monitoring; Oral anticoagulation; Platelet aggregation

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; DABIGATRAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; RIVAROXABAN; THROMBIN INHIBITOR; THROMBOCYTE RECEPTOR; TICAGRELOR;

ANALYZER; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; DIAGNOSTIC VALUE; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LIGHT TRANSMISSION AGGREGOMETRY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MULTIPLATE ANALYZER; PHASE 4 CLINICAL TRIAL (TOPIC); PLATELET MAPPING ASSAY; PROGNOSIS; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL (TOPIC); STENT THROMBOSIS; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY; VASODILATOR STIMULATED PHOSPHOPROTEIN ASSAY; BLOOD; BLOOD CLOTTING TEST; DOSE RESPONSE; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; PLATELET AGGREGATION INHIBITORS;

EID: 84896275898     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/HAMO-13-11-0055     Document Type: Article

References (32)

1. Sibbing D, Orban M, Massberg S. Potent P2Y12 receptor inhibitors in patients with acute coronary syndrome. Agents, indications, issues to consider in clinical practice. Hämostaseologie 2013; 33: 9-15.
2. Steiner T, Bohm M, Dichgans M et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol 2013; 102: 399-412.
3. Skov J, Bladbjerg EM, Rasmussen MA et al. Genetic, clinical and behavioural determinants of vitamin K-antagonist dose - Explored through multivariable modelling and visualization. Basic Clin Pharmacol Toxicol 2011; doi: 10.1111/j.1742-7843.2011.00789.x.
4. Ageno W, Gallus AS, Wittkowsky A et al. Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis. Chest 2012; 141 (2 Suppl): e44S-E88S.
5. Horsti J, Uppa H, Vilpo JA. Poor agreement among prothrombin time international normalized ratio methods: comparison of seven commercial reagents. Clin Chem 2005; 51: 553-560.
6. Chia S, Van Cott EM, Raffel OC et al. Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation. Thromb Haemost 2009; 101: 535-540.
7. Chew DP, Bhatt DL, LincoffAM et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 2001; 103: 961-966.
8. Castellone DD, Van Cott EM. Laboratory monitoring of new anticoagulants. Am J Hematol 2010; 85: 185-187.
9. Becker RC, Yang H, Barrett Y et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 2011; 32: 183-187.
10. Van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
11. Cannegieter SC, van der Meer FJ, Briet E et al. Warfarin and aspirin after heart-valve replacement. N Engl J Med 1994; 330: 507-509.
12. Erkens PM, ten Cate H, Buller HR et al. Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and metaanalysis. PLoS One 2012; 7: e42269.
13. Dentali F, Riva N, Crowther M et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012; 126: 2381-2391.
14. Reilly PA, Lehr T, Haertter S et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients in the RE-LY trial. J Am Coll Cardiol 2013; doi: 10.1016/j.jacc.2013.07.104.
15. Sibbing D, Taubert D, Schomig A et al. Pharmacokinetics of clopidogrel in patients with stent thrombosis. J Thromb Haemost 2008; 6: 1230-1232.
16. Freynhofer MK, Bruno V, Willheim M et al. Vasodilator-stimulated phosphoprotein-phosphorylation assay in patients on clopidogrel: does standardisation matter? Thromb Haemost 2012; 107: 538-544.
17. Jakubowski JA, Bourguet N, Boulay-Moine D et al. Comparison of a new ELISA assay with the flow cytometric assay for platelet vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation in whole blood to assess P2Y(12) inhibition. Thromb Haemost 2012; 107: 388-395.
18. Tantry US, Bonello L, Aradi D et al. Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding. J Am Coll Cardiol 2013; doi: 10.1016/j.jacc.2013.07.101.
19. Aradi D, Storey RF, Komocsi A et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 2013; doi: 10.1093/eurheartj/eht375.
20. Stone GW, Witzenbichler B, Weisz G et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPTDES). Lancet 2013; 382: 614-623.
21. Sibbing D, Gross L, Orban M, et al. Bleeding and thrombosis risk matters: how long can we stick to the one-size-fits-all strategy of platelet inhibition? JACC Cardiovasc Interv 2013; 6: 864-866.
22. Mangiacapra F, Patti G, Barbato E, et al. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE study. JACC Cardiovasc Interv 2012; 5: 281-289.
23. Campo G, Parrinello G, Ferraresi P et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011; 57: 2474-2483.
24. Sibbing D, Steinhubl SR, Schulz S et al. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol 2010; 56: 317-318.
25. Cuisset T, Grosdidier C, Loundou A et al. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study. JACC Cardiovasc Interv 2013; in press. doi: 10.1016/j.jcin.2013.04.009.
26. Bonello L, Mancini J, Pansieri M, et al. Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. J Thromb Haemost 2012; 10: 1999-2005.
27. Gurbel PA, Bliden KP, Navickas IA et al. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J 2010; 160: 346-354.
28. Price MJ, Berger PB, Teirstein PS et al. Standardvs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011; 305: 1097-1105.
29. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367: 2100-2109.
30. Trenk D, Stone GW, Gawaz M et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: Results of the TRIGGER-PCI study. J Am Coll Cardiol 2012; 59: 2159-2164.
31. Siller-Matula JM, Francesconi M, Dechant C et al. Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int J Cardiol 2013; 167: 2018-2023.
32. Bonello L, Camoin-Jau L, Arques S et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance. J Am Coll Cardiol 2008; 51: 1404-1411.